Zynerba Pharmaceuticals, Inc.
http://zynerba.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zynerba Pharmaceuticals, Inc.
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
All Over For Servier's Autism Ambitions
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.
Shionogi Set To Acquire R&D Partner Tetra After Raising Stake
Japanese firm sets stage to acquire US bioventure after it raises stake just ahead of key readout for lead asset.
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery